USP22 Antibody

What is USP22 and what are its key biological functions?

USP22 is a ubiquitin-specific peptidase that serves as a histone deubiquitinating component of the SAGA (Spt-Ada-Gcn5) transcriptional regulatory complex. The canonical human USP22 protein has 525 amino acid residues with a molecular mass of approximately 60 kDa . It is primarily localized in the nucleus and functions to deubiquitinate histones H2A and H2B, acting as a transcriptional coactivator. USP22 is recruited to specific gene promoters by activators such as MYC, where it regulates transcription .

USP22 plays multiple critical roles including:

• Regulation of cell cycle progression and chromatin organization

• Modulation of DNA repair pathways, particularly in class switch recombination

• Involvement in cancer progression and metastasis as part of the "Polycomb/cancer stem cell signature"

• Protection against myocardial ischemia-reperfusion injury via SIRT1/p53/SLC7A11 pathway

• Regulation of antibody class switching in B cells, with selective effects on different immunoglobulin isotypes

What is the molecular weight and tissue distribution pattern of USP22?

Molecular Characteristics:

• Canonical protein length: 525 amino acid residues

• Theoretical molecular weight: 60 kDa

• Observed molecular weight on Western blot: 58-60 kDa

• Alternative splicing yields 2 different isoforms

Tissue Distribution Pattern:

• High expression: Heart and skeletal muscle

• Low expression: Lung and liver

• Nuclear subcellular localization, consistent with its function in the SAGA complex

• Abnormally elevated expression in various cancers including oral squamous cell carcinoma (63.32% of 319 OSCC samples showed positive USP22 expression)

The expression level of USP22 is significantly upregulated during cancer progression, with a stepwise increase from non-cancerous mucosa to primary carcinoma and further to lymph node metastasis .

What are the recommended applications for USP22 antibodies?

Based on published literature and commercial antibody validation data, USP22 antibodies have been successfully used in the following applications:

These applications have been instrumental in uncovering USP22's roles in cancer progression, histone modification, transcriptional regulation, and immune responses.

How can researchers validate the specificity of USP22 antibodies?

Rigorous validation of USP22 antibodies is essential to ensure experimental reliability. Recommended validation approaches include:

• Western Blot Validation:

  • Confirm detection of a protein band at 58-60 kDa

  • Use positive control cell lines (A549 or HepG2 cells work effectively)

  • Include USP22 knockdown/knockout samples as negative controls

• Genetic Manipulation Controls:

  • Employ multiple shRNA constructs targeting different regions of USP22 transcript

  • As noted in one study: "These data are unlikely to result from off-target effects of the USP22 shRNA as identical results were obtained when USP22 was depleted using a second shRNA construct targeting a distinct region of the USP22 transcript"

• Functional Validation:

  • Test the antibody's ability to detect changes in H2B ubiquitination levels in USP22-depleted cells

  • Compare wild-type versus catalytically inactive USP22 effects

• Cross-Reactivity Assessment:

  • Examine reactivity in tissues known to have high (heart, skeletal muscle) versus low (lung, liver) USP22 expression

  • Test across multiple species if conducting comparative studies

• Immunoprecipitation-Mass Spectrometry:

  • Verify that the antibody pulls down authentic USP22 protein through mass spectrometry analysis

What controls should be included in USP22 antibody experiments?

Proper experimental controls are essential for interpretable results when using USP22 antibodies:

For Western Blotting:

• Positive controls: Lysates from A549 or HepG2 cells

• Loading controls: β-actin is commonly used across studies

• Knockdown/knockout controls: USP22-depleted samples

• Specificity control: Pre-absorption with immunizing peptide

For Immunohistochemistry:

• Positive tissue controls: Heart or skeletal muscle sections

• Negative tissue controls: Tissues with low expression

• Technical controls: Isotype-matched non-specific antibodies

• Scoring system: Implement a standardized scoring approach (e.g., the semiquantitative assessment used in OSCC studies: negative (−), 1–20% (+), 20–50% (++), 50–100% (+++) of cells stained)

For Protein Interaction Studies:

• DNA-independent controls: Include ethidium bromide and DNase I treatment to eliminate DNA-mediated interactions

• Reciprocal co-IPs: Perform bidirectional pull-downs to confirm interactions

• Unrelated protein controls: Include proteins unlikely to interact with USP22

For Enzymatic Activity Studies:

• Catalytically inactive USP22 mutants

• Recombinant USP22 protein (positive control)

• Mock-treated or unrelated enzyme controls

What are the optimal protocols for USP22 antibody use in Western blotting?

For optimal Western blot detection of USP22, the following protocol has been shown to be effective:

Sample Preparation:

• Lyse cells with cell lysis buffer (e.g., Sigma C0481)

• Incubate at 4°C for 30 minutes

• Centrifuge at 12,000 × g at 4°C for 15 minutes

• Collect supernatant and determine protein concentration using BCA assay

SDS-PAGE and Transfer:

• Heat 20 μg protein samples at 95°C for 5 minutes

• Separate proteins on a 10% SDS-PAGE gel

• Transfer to PVDF membrane

• Block with 5% skimmed milk powder for 1 hour

Antibody Incubation:

• Primary antibody dilution: 1:1000-1:6000 in TBST

• Incubate overnight at 4°C

• Wash 3× with TBST, 5 minutes each

• Secondary antibody dilution: 1:2000 HRP-labeled appropriate secondary antibody

• Incubate at room temperature for 1 hour

• Wash 3× with TBST, 5 minutes each

Detection and Analysis:

• Develop using ECL reagent

• Expected band: 58-60 kDa

• Use β-actin (1:4000 dilution) as loading control

• Analyze band intensity using ImageJ or similar software

This protocol has been successfully used to detect USP22 in various cell types and tissue samples across multiple studies.

What are the recommended immunohistochemistry protocols for USP22 detection in tissue samples?

For effective immunohistochemical detection of USP22 in tissue samples, researchers have successfully employed the following protocol:

Tissue Preparation:

• Use formalin-fixed, paraffin-embedded sections (4 μm thickness)

• Deparaffinize in xylene

• Rehydrate through graded ethanol solutions (100%, 95%, 70%, 50%)

Antigen Retrieval:

• Submerge sections in EDTA buffer (pH 8.0)

• Heat in autoclave at 121°C for 5 minutes

• Cool to room temperature

Staining Procedure:

• Quench endogenous peroxidase with 3% H₂O₂ for 15 minutes

• Wash with PBS

• Incubate with USP22 antibody (e.g., Abcam ab4812) at 1:200 dilution overnight at 4°C

• Wash with PBS

• Incubate with peroxidase-conjugated streptavidin for 30 minutes

• Visualize with diaminobenzidine (DAB)

• Counterstain with hematoxylin

Scoring and Evaluation:
Implement a semiquantitative assessment system:

• Negative (−): None of the cells stained

• (+): 1–20% of cells stained

• (++): 20–50% of cells stained

• (+++): 50–100% of cells stained

For binary analysis, scores can be categorized as:

• Negative expression: 0 ≤ score < 2+

• Positive expression: 2+ ≤ score < 3+

This IHC protocol has been successfully used to demonstrate the prognostic significance of USP22 in OSCC, revealing that patients with positive USP22 expression had significantly poorer outcomes compared to those with negative expression .

How can USP22 antibodies be used to study protein-protein interactions?

USP22 antibodies are valuable tools for investigating protein-protein interactions through several sophisticated approaches:

Co-Immunoprecipitation (Co-IP):

• Immunoprecipitate USP22 using specific antibodies from nuclear extracts

• Analyze co-precipitated proteins by Western blot

• This approach has successfully demonstrated USP22's association with SAGA complex components, including hGCN5

• For example: "Immunoprecipitation of USP22 from nuclear extracts of human cells revealed the specific coprecipitation of endogenous hGCN5"

Reciprocal Co-IP:

• Immunoprecipitate suspected binding partners (e.g., FBP1)

• Probe for USP22 in the precipitated complexes

• This strategy has confirmed USP22's interaction with FBP1: "FLAG-tagged FBP1 was immunoprecipitated from 293T nuclear extracts, and the eluted complexes were analysed by immunoblot for the presence of USP22"

DNA-Independent Interaction Validation:
To exclude DNA-mediated interactions:

• Include ethidium bromide (50 μg/ml) and DNase I treatment in IP experiments

• This control has been used to verify direct protein-protein interactions: "This experiment was conducted in the presence of ethidium bromide and DNase I treatment, to eliminate the possibility that the interaction between USP22 and FBP1 is mediated by DNA"

Chromatin Immunoprecipitation (ChIP):

• Use USP22 antibodies to identify genomic regions where USP22 is recruited

• This approach has shown that "USP22 is recruited to specific genes by activators such as the MYC oncoprotein, where it is required for transcription"

These approaches have established USP22's interactions with the SAGA complex components and other proteins like FBP1, revealing its complex role in transcriptional regulation and cellular processes.

How can researchers investigate USP22's role in histone deubiquitination?

Investigating USP22's histone deubiquitination activity requires specialized approaches:

In Vitro Deubiquitination Assays:

• Purify recombinant USP22 or immunoprecipitate USP22-containing complexes

• Incubate with ubiquitinated histone substrates

• Analyze deubiquitination by Western blot

• As demonstrated in one study: "When used in the in vitro uH2B deubiquitination assay, recombinant USP22 showed specific ubiquitin hydrolase activity towards uH2B"

SAGA Complex Deubiquitination Activity:

• Purify the SAGA complex from control and USP22-depleted cells

• Test deubiquitinating activity on ubiquitinated histone substrates

• This approach revealed: "When purified from cells expressing reduced levels of USP22, the ubiquitin hydrolase activity of the hSAGA complex was also reduced"

Analysis of Histone Ubiquitination in Vivo:

• Generate USP22 knockout or knockdown cells/animals

• Analyze histone ubiquitination levels by Western blot

• This approach showed: "Consistent with its role in deubiquitinating H2B, we found that the level of H2Bub was markedly increased in splenic B cells from CD19-cre-Usp22 KO mice"

• Specific detection using: "mouse monoclonal antibody against H2BK120Ub (Millipore, clone: 56, catalog number: 05-1312; 1/1000 dilution), or rabbit polyclonal antibody against total H2B"

Temporal Analysis After Stimulation:

• Stimulate cells and collect at various timepoints

• Analyze H2Bub levels by Western blot

• Example protocol: "The purified spleen B cells were first stimulated with LPS for 2.5 days, exposed to 8 Grays of γ-radiation, and then collected at various time points for western blotting"

Mutational Analysis:

• Compare wild-type USP22 with catalytically inactive mutants

• Analyze effects on histone ubiquitination and cellular processes

• This approach has confirmed USP22's enzymatic function: "Expression of wild-type–USP22 led to a decrease in Ub-FBP1 levels, whereas expression of catalytically inactive USP22 had no effect"

These methodologies have established USP22 as a key histone deubiquitinase within the SAGA complex, with important implications for transcriptional regulation and cellular function.

What methodologies are effective for studying USP22's role in cancer progression?

USP22 has emerged as an important marker and potential therapeutic target in cancer research. The following methodologies have proven effective for investigating its role:

Clinical Sample Analysis:

• Immunohistochemistry on large patient cohorts

• Scoring system: negative (−), 1–20% (+), 20–50% (++), 50–100% (+++) of cells stained

• Correlation with clinicopathological parameters

• This approach revealed: "positive USP22 expression was positively related to lymph node metastasis, Ki67, Cox-2 and recurrence"

Cancer Progression Analysis:

• Compare USP22 expression across disease stages

• In OSCC, "USP22 expression increased significantly from normal mucosa to carcinomas and from carcinomas to lymph node metastasis"

Survival and Prognostic Analysis:

Functional Studies in Cancer Cell Lines:

• USP22 knockdown or overexpression

• Analysis of cancer hallmarks:

  • Proliferation: "USP22 silencing decreased cell proliferation and clonogenesis by 3-folds"

  • Migration/invasion: "USP22 overexpression enhanced cell migration and invasion by ~2–4 folds"

  • EMT markers: "USP22 overexpression downregulated E-cadherin and upregulated vimentin"

Molecular Mechanism Investigation:

• Identify cancer-relevant USP22 substrates

• Analyze effects on signaling pathways

• Studies have identified multiple mechanisms:

  • In hepatocellular carcinoma: USP22 interaction with FKBP12

  • In acute promyelocytic leukemia: USP22 regulation of PML-RARα stability

  • In oral cancer: relationship with Ki-67 and COX-2 expression

Therapeutic Response Studies:

• Analyze USP22's impact on treatment efficacy

• In liver transplant patients: "the effect of sirolimus on prognosis depending on USP22 expression"

These methodologies collectively provide a comprehensive approach to understanding USP22's role in cancer and identifying potential therapeutic opportunities.

How can researchers explore USP22's role in antibody class switch recombination?

USP22 plays a unique role in antibody class switch recombination (CSR), with differential effects on various immunoglobulin isotypes. To investigate this function:

Conditional Knockout Models:

• Generate B-cell-specific USP22 knockout mice (e.g., CD19-cre-Usp22 KO mice)

• Verify knockout efficiency by qPCR and Western blot

• Analyze histone ubiquitination: "the level of H2Bub was markedly increased in splenic B cells from CD19-cre-Usp22 KO mice"

Ex Vivo Class Switch Recombination Assays:

• Isolate splenic B cells from USP22 knockout and control mice

• Stimulate with appropriate cytokines to induce switching to different isotypes:

  • LPS + IL-4 for IgG1

  • LPS + TGF-β for IgA

  • LPS + IFN-γ for IgG2a

• Analyze isotype switching by flow cytometry

• These assays revealed: "Usp22 KO splenic B cells are defective in almost all the isotypes, except IgA"

Analysis of Mutation Patterns in Switch Regions:
Sequence analysis of switch regions revealed specific patterns:

Table adapted from source

In Vivo Immunization Studies:

• Immunize mice with T-dependent antigens (e.g., NP-CGG in alum)

• Collect serum at various timepoints

• Analyze antigen-specific antibody responses by ELISA and ELISPOT

• Compare high-affinity vs. total antibody responses using NP4-BSA vs. NP32-BSA coating

Analysis of AID Expression:

• Measure AID expression by qPCR and Western blot in USP22-deficient B cells

• Using "mouse anti-AID monoclonal antibody (Cell Signaling Technology, clone: L7E7)"

These approaches have revealed USP22's selective role in antibody class switching, suggesting potential therapeutic applications: "USP22 could be exploited as a therapeutic target in IgG or IgE-mediated autoimmune diseases, such as systemic lupus erythematosus, autoimmune thrombocytopenia, and asthma" while potentially "without disturbing the homeostasis of the gut microbiota" .

How can USP22 antibodies be used to investigate transcriptional regulation mechanisms?

USP22's role in the SAGA complex positions it as a key regulator of transcription. To investigate this function:

Chromatin Immunoprecipitation (ChIP):

• Use USP22 antibodies to identify genomic regions where USP22 is recruited

• Research has shown that "USP22 is recruited to specific genes by activators such as the MYC oncoprotein, where it is required for transcription"

• Compare USP22 binding with histone modification patterns, particularly H2B ubiquitination

SAGA Complex Purification:

• Generate stable cell lines expressing tagged SAGA components (e.g., hGCN5)

• Purify the complex and confirm USP22 association

• As demonstrated: "hSAGA was purified as described previously using a 293T cell line stably expressing an epitope-tagged version of the hGCN5 subunit"

• Analyze the complex composition and enzymatic activities

Co-recruitment Studies:

• Examine USP22 recruitment in relation to specific transcription factors

• This approach has shown that "USP22 is recruited to specific genes by activators such as the MYC oncoprotein"

• Use sequential ChIP (re-ChIP) to confirm co-occupancy of factors

Target Gene Expression Analysis:

• Perform RNA-seq or qPCR on USP22-depleted vs. control cells

• Studies have identified specific targets: "USP22 affects the expression of p21 by altering far upstream element (FUSE)-binding protein 1 (FBP1) ubiquitination"

• Correlate gene expression changes with alterations in histone modifications

Deubiquitination of Transcriptional Regulators:

• Analyze ubiquitination status of transcription factors in USP22-depleted cells

• One study showed: "We overexpressed haemagglutinin-tagged ubiquitin (HA-Ub) in USP22-depleted and control 293T cells. Ubiquitinated proteins were then purified using an anti-HA affinity matrix, and the precipitated fractions were analysed by immunoblot for FBP1"

• Compare effects of wild-type vs. catalytically inactive USP22

Analysis of Histone Modifications at Target Genes:

• Perform ChIP for H2Bub at USP22-regulated genes

• Compare modification levels in control vs. USP22-depleted cells

• Correlate with transcriptional activity

These approaches have established USP22 as a critical component of transcriptional regulation through its deubiquitinating activity toward histones and transcriptional regulators, with important implications for gene expression programs in development and disease.